FICHIT

Je m'inscris

SENSORION

0/5 (0 note(s))
Note donnée : aucune
Paris
35
Spun off from Inserm (the French institute of health and medical research) in 2009, Sensorion is a biotech that specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss.
The company’s lead drug candidate, SENS-111, is a small molecule which aims to treat acute vertigo. It is the first representative of the histamine type 4 receptor antagonist class tested in inner-ear pathologies. It can be taken orally and has just been successfully assessed in humans in phase 1b clinical trial.
NGUYEN Laurent
www.sensorion-pharma.com
ALSEN:FP

Fiche créée le 10/04/2016 par Guillaume   vue 6 fois.